Brand name
Atacand HCT, the original
We didn’t find a savings card or cash price from Atacand HCT’s maker. Ask the pharmacy for Atacand HCT’s cash price. With insurance, ask what your plan charges.
Generic name: candesartan cilexetil and hydrochlorothiazide
Used for: High blood pressure
From
$21.12 for 30 tablets delivered ($15.87 plus $5.25 shipping)
Generic candesartan cilexetil and hydrochlorothiazide from Cost Plus Drugs, by mail. Pick the strength on your label for its own price.
Need it today? From $25.19 for 30 tablets with the free Team Cuban Card, at pharmacies that take it. Get the free card and show it there.
See the price and get the cardA regular generic has the same active ingredient as Atacand HCT, and the FDA requires it to work the same way.
Atacand HCT, the original
We didn’t find a savings card or cash price from Atacand HCT’s maker. Ask the pharmacy for Atacand HCT’s cash price. With insurance, ask what your plan charges.
The same medicine as Atacand HCT, without the brand name
The same medicine as Atacand HCT, without the brand name. Its NDC is the number that names the exact product: give it to the pharmacy and they can look it up or order it.
candesartan cilexetil and hydrochlorothiazide
Pick your strength
Give the pharmacy this NDC
What to say at the pharmacy
“Before you fill my Atacand HCT, can you tell me what I’d pay for the brand, for the authorized generic from ANI Pharmaceuticals (NDC ), and for a regular generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Source: FDA, updated November 16, 2026
Official labels and ingredient lists from DailyMed (U.S. National Library of Medicine).
16 mg / 12.5 mg tablet
Same active and inactive ingredients as Atacand HCT.
Active: candesartan cilexetil 16 mg · hydrochlorothiazide 12.5 mg
Inactive, on both labels:
32 mg / 12.5 mg tablet
Same active and inactive ingredients as Atacand HCT.
Active: candesartan cilexetil 32 mg · hydrochlorothiazide 12.5 mg
Inactive, on both labels:
32 mg / 25 mg tablet
Same active and inactive ingredients as Atacand HCT.
Active: candesartan cilexetil 32 mg · hydrochlorothiazide 25 mg
Inactive, on both labels:
Same active ingredient as Atacand HCT. Fillers and dyes can differ.
Pharmacies’ own cash prices for generic candesartan cilexetil and hydrochlorothiazide, lowest first.
Pick up in storeDelivered
From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.
Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.
3 companies sell a generic of Atacand HCT that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
Has lactose
16 mg / 12.5 mg Pink, oval, 10 mm, marked “ML71”
| Package | NDC |
|---|---|
| Bottle of 90 | 33342-131-10 |
| Carton of 100 | 33342-131-12 |
| Bottle of 300 | 33342-131-51 |
| Bottle of 500 | 33342-131-15 |
32 mg / 12.5 mg Yellow, oval, 11 mm, marked “ML58”
| Package | NDC |
|---|---|
| Bottle of 90 | 33342-132-10 |
| Carton of 100 | 33342-132-12 |
| Bottle of 300 | 33342-132-51 |
| Bottle of 500 | 33342-132-15 |
32 mg / 25 mg Pink, oval, 11 mm, marked “ML57”
| Package | NDC |
|---|---|
| Bottle of 90 | 33342-133-10 |
| Carton of 100 | 33342-133-12 |
| Bottle of 300 | 33342-133-51 |
| Bottle of 500 | 33342-133-15 |
Inactive ingredients: carboxymethylcellulose calcium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, starch, corn, glycerin, ferric oxide red, ferric oxide yellow
Has lactose · Made by Pharmobedient Consulting · Being phased out; sold until February 2027
16 mg / 12.5 mg Peach mottled, round, 7 mm, marked “M / X / C1”
| Package | NDC |
|---|---|
| Bottle of 90 | 0378-3001-77 |
Inactive ingredients: carboxymethylcellulose calcium, starch, corn, glyceryl monostearate, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, ferric oxide red, ferric oxide yellow
Has lactose · Made by Prinston Pharmaceutical
16 mg / 12.5 mg White to off-white, oval, 10 mm, marked “588 / P”
| Package | NDC |
|---|---|
| Bottle of 90 | 43547-459-09 |
| Bottle of 500 | 43547-459-50 |
32 mg / 12.5 mg Yellow, oval, 11 mm, marked “589 / P”
| Package | NDC |
|---|---|
| Bottle of 90 | 43547-460-09 |
| Bottle of 500 | 43547-460-50 |
32 mg / 25 mg White to off-white, oval, 11 mm, marked “590 / P”
| Package | NDC |
|---|---|
| Bottle of 90 | 43547-461-09 |
| Bottle of 500 | 43547-461-50 |
Inactive ingredients: carboxymethylcellulose calcium, hydroxypropyl cellulose (1600000 wamw), lactose monohydrate, microcrystalline cellulose, magnesium stearate, polyethylene glycol 6000, starch, corn, ferric oxide yellow, hydroxypropyl cellulose (160000 wamw)
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).
Source: the FDA label for Atacand HCT (ANI Pharmaceuticals, Inc.), December 22, 2025. Full label on DailyMed
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/atacand-hct/